Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in primary mitochondrial disease due to pathogenic nuclear DNA mutations
2021-003907-16Phase 3Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mitochondriopathy comparing Elamipretide with Placebo (2 arms). Started Jan 2022; status: completed.
02
Drugs
elamipretide
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on 2021-003907-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003907-16.